Toronto · Independent Shariah screening · Screened September 30, 2026

Screened September 30, 2026 · TSX: BLCO · Q2 2026 results

Debt ÷ market cap 83.6% / 33%
Non-compliant income 0.29% / 5%

Bausch + Lomb Corporation

BLCO · TSX · Healthcare

FAIL

Is Bausch + Lomb Corporation (BLCO) halal?

Bausch + Lomb Corporation (TSX/NYSE: BLCO; headquartered in Vaughan, Ontario) is a global eye-health company — Vision Care (contact lenses and consumer eye products, US$784M Q2 2026), Surgical devices (US$256M), and ophthalmic Pharmaceuticals (US$354M) — a clean business with no prohibited segments. But interest-bearing debt of ~US$5.12B against a ~US$6.12B market cap gives a debt ratio of ~83.6%, far above the ~33% AAOIFI ceiling. The income gate passes (interest income ~0.29% of revenue). The FAIL comes from the debt gate alone — a result Zoya and ShariaPortfolio both independently reach. Data from Q2 2026 results, screened September 30, 2026.

Price chart by TradingView · Market data may be delayed · Shown for information only — not investment advice.

The two-gate Shariah screen

Every screener on this site runs the same two gates: first, the business must be halal (no conventional insurance, banking, alcohol, gambling, weapons manufacturing, and the like); second, the financial ratios must clear (debt under roughly 33% of market cap, non-compliant income under roughly 5%).

Gate one: the business — eye health, passes

Bausch + Lomb is a pure healthcare company with about 13,000 employees and three reportable segments (Q2 2026 company press release, July 29, 2026):

No alcohol, gambling, conventional finance or insurance, pork, weapons or defense, adult entertainment, or tobacco anywhere in the business. The business gate passes.

Gate two: the ratios — debt fails decisively

The business and income gates pass — the FAIL comes from the debt gate alone. (Context: the January 2026 refinancing replaced US$2.8B of term B loans with new facilities maturing January 2031, cutting the margin but not the leverage; the company has reported persistent GAAP losses and an accumulated deficit of ~US$1.016B. Bausch Health Companies Inc. holds ~87% of BLCO's shares and reiterates a long-planned separation/distribution of that stake.)

What other screeners say

The bottom line

This screener gives Bausch + Lomb Corporation (TSX: BLCO) a FAIL. The eye-health business is clean and the income gate passes (interest income ~0.29%), but ~US$5.12B of debt against a ~US$6.12B market cap is ~83.6% — about two and a half times the ~33% ceiling. Zoya and ShariaPortfolio independently reach the same non-compliant rating. Snapshot dated September 30, 2026; re-checked quarterly after earnings.

BDS screen

Whether this company appears on boycott, divestment and sanctions (BDS) lists. Informational only — it does not change the Shariah screening result above, and it is not a religious ruling.

No BDS listing found on the BDS movement's published boycott, divestment, or pressure lists (checked October 2026).

Moral screen

Beyond the Shariah financial gates, this checks the company’s documented business ties to the Israeli and US militaries, and to weapons manufacturing. Every finding is factual and sourced. A row with no finding means none surfaced in our review — not proof of none.

Israeli military business
No findings published.
US military business
No findings published.
Weapons manufacturing & arms trade
No findings published.

Halal alternatives in this sector

BLCO did not pass the screen. These companies in the same sector passed:

Sources

Related screeners

Frequently asked questions

Is Bausch + Lomb (BLCO) halal?

Our screener gives Bausch + Lomb Corporation a FAIL screening result. The business — eye health (Vision Care contact lenses and consumer eye products, Surgical devices, ophthalmic Pharmaceuticals) — is clean, and the income gate passes (interest income US$4M vs US$1,394M Q2 revenue = 0.29%). But interest-bearing debt of ~US$5.12B against a ~US$6.12B market cap gives a debt ratio of ~83.6%, far above the ~33% AAOIFI ceiling. Note: BLCO is dual-listed on the NYSE and the TSX (TSX: BLCO), headquartered in Vaughan, Ontario.

Why does Bausch + Lomb fail the debt gate?

At June 30, 2026 the company carried about US$5,115M of interest-bearing debt (current portion of long-term debt US$43M plus long-term debt US$5,072M) against a market cap of only ~US$6.12B (357,165,000 shares at US$17.14, September 29, 2026). The ratio is ~83.6% — about two and a half times the ~33% AAOIFI ceiling. Including lease liabilities (~US$163M, last disclosed in the FY2025 10-K) gives ~86%, still a fail.

Do Bausch + Lomb's other ratios pass?

Yes. Interest income is separately disclosed in the Q2 2026 statements: US$4M against total revenue of US$1,394M = ~0.29% — under the ~5% AAOIFI ceiling (six months: US$8M). Cash and cash equivalents of US$367M are ~6.0% of market cap — under the ~33% cash-plus-securities ceiling. The FAIL comes from the debt gate alone.

What do Zoya, Musaffa and ShariaPortfolio say about Bausch + Lomb?

Zoya covers BLCO and rates it not Shariah-compliant. ShariaPortfolio's screener covers BLCO and rates it not Shariah-compliant, citing failed financial ratios — consistent with this screener's debt-gate FAIL. We found no Musaffa rating page for BLCO as of September 30, 2026. Our screener reports its own figure-by-figure analysis above.

Could Bausch + Lomb become halal?

Only if the debt load shrinks materially. The January 2026 refinancing (US$2.8B replacement term B loans, maturing January 2031) extended maturities but did not reduce leverage. Bausch Health Companies holds ~87% of BLCO's shares and reiterates a long-planned separation/distribution of that stake — a change in ownership would not by itself change the debt math. Re-screen after a material deleveraging or a large equity raise.